BioCentury | May 10, 2019
Emerging Company Profile

HopeMed: Targeting PRLR for chronic diseases

...than existing interventions. No other companies have disclosed developing PRLR inhibitors for endometriosis or alopecia. Xoma Corp....
...Bayer AG (Xetra:BAYN), Leverkusen, Germany Oncolix Inc. (Pink:ONCX), Houston, Texas Peking University, Beijing, China Xoma Corp. (NASDAQ:XOMA...
...Prolactin PRLR - Prolactin receptor Hongjiang Li, Staff Writer BAY 1158061 AbbVie Inc. Bayer AG Hope Medicine Inc. Oncolix Inc. Peking University Xoma Corp. 5-alpha...
BioCentury | Apr 12, 2019
Company News

Xoma gains milestone and royalty rights to Aronora's hematology assets

...payments and a portion of potential milestones associated with five hematology assets from Aronora. Xoma Corp. (NASDAQ:XOMA...
...single-digit royalties. Aronora Inc. (Portland, Ore.) is eligible for an additional $3 million payment from Xoma...
...Aronora is partnered with Bayer AG (Xetra:BAYN) on three of the assets. Shannon Lehnbeuter, Staff Writer Aronora Inc. Xoma...
BioCentury | Dec 14, 2018
Product R&D

Gene therapy’s make or buy choice

...gene therapy manufacturing infrastructure is where antibody manufacturing was 20 years ago, when companies like Xoma Corp....
...to do their own production. Ransohoff is a chemical engineer who conducted GMP manufacturing at Xoma...
...U.S. Food and Drug Administration (FDA), Silver Spring, Md. Vanrx Pharmasystems Inc., Burnaby, B.C. Xoma Corp. (NASDAQ:XOMA...
BioCentury | Jan 9, 2018
Company News

Management tracks: OncoMed, Neurocrine

...Pharmaceuticals U.S. division at Actelion Ltd., which Johnson & Johnson (NYSE:JNJ) acquired. Antibody developer Xoma Corp. (NASDAQ:XOMA...
BioCentury | Sep 1, 2017
Company News

Xoma, Novartis partner for IL-1 beta mAbs and related IP

...Xoma Corp. (NASDAQ:XOMA), Berkeley Calif. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Cardiovascular, Antibodies Jaime De Leon ACZ885 canakinumab gevokizumab Ilaris S 78989 XOMA...
...NASDAQ:XOMA), Berkeley Calif. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Cardiovascular, Antibodies Jaime De Leon ACZ885 canakinumab gevokizumab Ilaris S 78989 XOMA 052 XOMA...
...Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Cardiovascular, Antibodies Jaime De Leon ACZ885 canakinumab gevokizumab Ilaris S 78989 XOMA 052 XOMA 089 XOMA 358 Novartis AG Servier Xoma Corp. Insulin...
BioCentury | Aug 28, 2017
Clinical News

Canakinumab reduces lung cancer mortality, headed for Phase III

...Last week, Xoma Corp. (NASDAQ:XOMA) granted Novartis worldwide commercial rights to another IL-1 beta mAb, gevokizumab (XOMA...
...as well as an exclusive license to IP covering IL-1 beta-targeting antibodies for CV disease. Xoma...
...no ongoing trials of gevokizumab (see BioCentury Extra, Aug. 25) . Jaime De Leon ACZ885 canakinumab gevokizumab Ilaris S 78989 XOMA 052 Novartis AG Xoma Corp. Interleukin-1...
BioCentury | Aug 25, 2017
Company News

Xoma gains on Novartis IL-1 beta mAb deals

...Xoma Corp. (NASDAQ:XOMA) jumped $2.17 (24%) to $11.10 on Friday after granting Novartis AG (NYSE:NVS; SIX:NOVN...
...owed to the pharma by Xoma. The debt stems from a $50 million loan facility Xoma...
...to treat periodic fever syndromes and systemic juvenile idiopathic arthritis. Jaime De Leon ACZ885 canakinumab gevokizumab Ilaris S 78989 XOMA 052 XOMA 089 Novartis AG Xoma Corp. Interleukin-1...
BioCentury | Mar 17, 2017
Clinical News

XOMA 358: Ph II data

...single doses of 3, 6 and 9 mg/kg IV XOMA 358 were generally well tolerated. XOMA...
...XOMA 358. The trial also includes a multiple-dose portion and is enrolling about 20 patients. Xoma Corp....
...includes a multiple-dose portion and is enrolling about 20 patients. Xoma Corp. (NASDAQ:XOMA), Berkeley, Calif. Product: XOMA...
BioCentury | Mar 17, 2017
Clinical News

XOMA 358: Additional Ph II data

...Xoma previously reported that XOMA 358 was well tolerated (see BioCentury, Oct. 3, 2016 ). Xoma Corp....
...previously reported that XOMA 358 was well tolerated (see BioCentury, Oct. 3, 2016 ). Xoma Corp. (NASDAQ:XOMA...
...358 was well tolerated (see BioCentury, Oct. 3, 2016 ). Xoma Corp. (NASDAQ:XOMA), Berkeley, Calif. Product: XOMA...
BioCentury | Feb 16, 2017
Financial News

Xoma completes direct public offering

...Antibody developer Xoma Corp. (NASDAQ:XOMA) raised $25 million through the sale of 1.2 million shares at $4.03...
...its affiliates on Feb. 13. The preferred stock converts at $4.03. Xoma Corp. (NASDAQ:XOMA), Berkeley, Calif. Alex Himes Xoma Corp....
Items per page:
1 - 10 of 754
BioCentury | May 10, 2019
Emerging Company Profile

HopeMed: Targeting PRLR for chronic diseases

...than existing interventions. No other companies have disclosed developing PRLR inhibitors for endometriosis or alopecia. Xoma Corp....
...Bayer AG (Xetra:BAYN), Leverkusen, Germany Oncolix Inc. (Pink:ONCX), Houston, Texas Peking University, Beijing, China Xoma Corp. (NASDAQ:XOMA...
...Prolactin PRLR - Prolactin receptor Hongjiang Li, Staff Writer BAY 1158061 AbbVie Inc. Bayer AG Hope Medicine Inc. Oncolix Inc. Peking University Xoma Corp. 5-alpha...
BioCentury | Apr 12, 2019
Company News

Xoma gains milestone and royalty rights to Aronora's hematology assets

...payments and a portion of potential milestones associated with five hematology assets from Aronora. Xoma Corp. (NASDAQ:XOMA...
...single-digit royalties. Aronora Inc. (Portland, Ore.) is eligible for an additional $3 million payment from Xoma...
...Aronora is partnered with Bayer AG (Xetra:BAYN) on three of the assets. Shannon Lehnbeuter, Staff Writer Aronora Inc. Xoma...
BioCentury | Dec 14, 2018
Product R&D

Gene therapy’s make or buy choice

...gene therapy manufacturing infrastructure is where antibody manufacturing was 20 years ago, when companies like Xoma Corp....
...to do their own production. Ransohoff is a chemical engineer who conducted GMP manufacturing at Xoma...
...U.S. Food and Drug Administration (FDA), Silver Spring, Md. Vanrx Pharmasystems Inc., Burnaby, B.C. Xoma Corp. (NASDAQ:XOMA...
BioCentury | Jan 9, 2018
Company News

Management tracks: OncoMed, Neurocrine

...Pharmaceuticals U.S. division at Actelion Ltd., which Johnson & Johnson (NYSE:JNJ) acquired. Antibody developer Xoma Corp. (NASDAQ:XOMA...
BioCentury | Sep 1, 2017
Company News

Xoma, Novartis partner for IL-1 beta mAbs and related IP

...Xoma Corp. (NASDAQ:XOMA), Berkeley Calif. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Cardiovascular, Antibodies Jaime De Leon ACZ885 canakinumab gevokizumab Ilaris S 78989 XOMA...
...NASDAQ:XOMA), Berkeley Calif. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Cardiovascular, Antibodies Jaime De Leon ACZ885 canakinumab gevokizumab Ilaris S 78989 XOMA 052 XOMA...
...Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Cardiovascular, Antibodies Jaime De Leon ACZ885 canakinumab gevokizumab Ilaris S 78989 XOMA 052 XOMA 089 XOMA 358 Novartis AG Servier Xoma Corp. Insulin...
BioCentury | Aug 28, 2017
Clinical News

Canakinumab reduces lung cancer mortality, headed for Phase III

...Last week, Xoma Corp. (NASDAQ:XOMA) granted Novartis worldwide commercial rights to another IL-1 beta mAb, gevokizumab (XOMA...
...as well as an exclusive license to IP covering IL-1 beta-targeting antibodies for CV disease. Xoma...
...no ongoing trials of gevokizumab (see BioCentury Extra, Aug. 25) . Jaime De Leon ACZ885 canakinumab gevokizumab Ilaris S 78989 XOMA 052 Novartis AG Xoma Corp. Interleukin-1...
BioCentury | Aug 25, 2017
Company News

Xoma gains on Novartis IL-1 beta mAb deals

...Xoma Corp. (NASDAQ:XOMA) jumped $2.17 (24%) to $11.10 on Friday after granting Novartis AG (NYSE:NVS; SIX:NOVN...
...owed to the pharma by Xoma. The debt stems from a $50 million loan facility Xoma...
...to treat periodic fever syndromes and systemic juvenile idiopathic arthritis. Jaime De Leon ACZ885 canakinumab gevokizumab Ilaris S 78989 XOMA 052 XOMA 089 Novartis AG Xoma Corp. Interleukin-1...
BioCentury | Mar 17, 2017
Clinical News

XOMA 358: Ph II data

...single doses of 3, 6 and 9 mg/kg IV XOMA 358 were generally well tolerated. XOMA...
...XOMA 358. The trial also includes a multiple-dose portion and is enrolling about 20 patients. Xoma Corp....
...includes a multiple-dose portion and is enrolling about 20 patients. Xoma Corp. (NASDAQ:XOMA), Berkeley, Calif. Product: XOMA...
BioCentury | Mar 17, 2017
Clinical News

XOMA 358: Additional Ph II data

...Xoma previously reported that XOMA 358 was well tolerated (see BioCentury, Oct. 3, 2016 ). Xoma Corp....
...previously reported that XOMA 358 was well tolerated (see BioCentury, Oct. 3, 2016 ). Xoma Corp. (NASDAQ:XOMA...
...358 was well tolerated (see BioCentury, Oct. 3, 2016 ). Xoma Corp. (NASDAQ:XOMA), Berkeley, Calif. Product: XOMA...
BioCentury | Feb 16, 2017
Financial News

Xoma completes direct public offering

...Antibody developer Xoma Corp. (NASDAQ:XOMA) raised $25 million through the sale of 1.2 million shares at $4.03...
...its affiliates on Feb. 13. The preferred stock converts at $4.03. Xoma Corp. (NASDAQ:XOMA), Berkeley, Calif. Alex Himes Xoma Corp....
Items per page:
1 - 10 of 754